Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Silbersher et al v. Allergan plc et al
Case Number:
3:18-cv-03018
Court:
Nature of Suit:
Judge:
Firms
- Berger Montague
- Brown Neri
- Burns Charest
- Clement & Murphy
- DLA Piper
- Gibson Dunn
- Goldstein & Russell
- Herrera Kennedy
- Joseph Saveri Law Firm
- King & Spalding
- Kirkland & Ellis
- Steven Williams Law
- Tycko & Zavareei
Companies
Government Agencies
Sectors & Industries:
-
March 13, 2023
Allergan Gets FCA Suit Tossed On Remand From 9th Circ.
A California federal judge has thrown out a patent attorney's whistleblower suit against Allergan over dementia drug patents on remand from the Ninth Circuit, finding Monday that the public disclosure bar sinks the attorney's claims.
-
August 25, 2022
9th Circ. Gives Allergan 2nd Chance To Ax FCA Suit
The Ninth Circuit has reversed a lower court decision that shut down pharmaceutical giant Allergan's bid to toss a patent attorney's whistleblower suit over dementia drug patents, determining Thursday that the attorney's claims tied to information from a patent proceeding trigger the public disclosure bar.
-
January 14, 2021
Patent Atty Slams Allergan Bid For Quick Appeal In FCA Case
A patent attorney has urged a California federal judge to reject Allergan's bid to immediately appeal a ruling requiring the pharmaceutical giant to face a False Claims Act suit over patents for dementia medications, arguing the appeal would unnecessarily delay trial.
-
January 04, 2021
Allergan Seeks Quick Appeal After Failing To Nix FCA Suit
Allergan urged a California federal judge to allow it to immediately appeal his ruling requiring the pharmaceutical giant to face a False Claims Act suit over dementia drugs, arguing that decisions expected from separate, ongoing litigation could potentially resolve the suit brought by a patent attorney against the drugmaker.
-
December 11, 2020
Allergan Must Face FCA Claims Over Dementia Drug Patents
A California federal judge rejected Allergan's bid to dodge a False Claims Act lawsuit Friday, finding the patent attorney behind the suit sufficiently alleged that the pharmaceutical company fraudulently obtained two dementia drug patents to allegedly monopolize pricing and out-compete generics.
-
June 09, 2020
Calif. Backs Patent Atty's Whistleblower Suit Against Allergan
California is supporting an attorney who filed a whistleblower lawsuit against Allergan Inc. alleging the pharmaceutical company fraudulently obtained patents to thwart generic competition and keep prices high, saying the attorney's claims could have a big impact on how much insurers pay for drugs.